Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18769915 | 0.79 | ALDH1A1 (0.38) | NOS1 | |
| SCHEMBL19756642 | 0.79 | NOS1 (0.39) | NOS1 | |
| SCHEMBL12344050 | 0.76 | IKBKB (0.32) | — | |
| SCHEMBL29504669 | 0.74 | KDM4E (0.51) | — | |
| SCHEMBL6674194 | 0.72 | MAPK1 (0.35) | — | |
| SCHEMBL29808187 | 0.72 | MAPK1 (0.35) | — | |
| SCHEMBL6224492 | 0.72 | KDR (0.46) | — | |
| SCHEMBL29512116 | 0.71 | MEN1 (0.38) | — | |
| SCHEMBL29504661 | 0.70 | LMNA (0.43) | — | |
| SCHEMBL30396198 | 0.70 | POLB (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221841-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8580828-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | NOS1 4734/4885CYP1A2 4500/4885CYP2A6 4601/4885 |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | NOS1 4721/4885CYP1A2 4289/4885CYP2A6 4528/4885 |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | NOS1 4721/4885CYP1A2 4289/4885CYP2A6 4528/4885 |
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | NOS1 2366/4885CYP1A2 112/4885CYP2A6 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.